Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum VALEANT PHARMACEUTICALS INTL INC T.VRX

"Valeant Pharmaceuticals is a global specialty pharmaceutical firm with a focus on branded products for the dermatology, gastrointestinal, and ophthalmology markets. The firm also has a branded generics business that operates primarily in Latin America, Eastern Europe, and Asia."

TSX:VRX - Post Discussion

VALEANT PHARMACEUTICALS INTL INC > Vrx in my view will be at $14.50-$15
View:
Post by mtgfree1 on Sep 28, 2017 10:00am

Vrx in my view will be at $14.50-$15

Be careful
Comment by mtgfree1 on Sep 29, 2017 9:14am
Be careful, 
Comment by TheGreatKazoo on Oct 09, 2017 11:47am
MTGfree is no dummy!  But are you tired of all the dumdums on this site?  The Great Kazoo has to go back to his planet but has now returned! 
Comment by mtgfree1 on Oct 11, 2017 10:01am
Investor to investor 
Comment by mtgfree1 on Oct 16, 2017 9:42am
that is Canadian dollars 
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities